Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

Mi Jeong Kwon, Jeong Eon Lee, Joon Jeong, Sang Uk Woo, Jinil Han, Byeong Il Kang, Jee Eun Kim, Youngho Moon, Sae Byul Lee, Seonghoon Lee, Yoon La Choi, Youngmi Kwon, Kyoung Song, Gyungyub Gong, Young Kee Shin

Research output: Contribution to journalArticle

Abstract

Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared. Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%) as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer. Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.

Original languageEnglish
Article number667
JournalFrontiers in Oncology
Volume9
DOIs
Publication statusPublished - 2019 Jul 24

Fingerprint

Hormones
Breast Neoplasms
Recurrence
Lymph Nodes
human ERBB2 protein
Korea
Paraffin
Formaldehyde
Drug Therapy
Population

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kwon, Mi Jeong ; Lee, Jeong Eon ; Jeong, Joon ; Woo, Sang Uk ; Han, Jinil ; Kang, Byeong Il ; Kim, Jee Eun ; Moon, Youngho ; Lee, Sae Byul ; Lee, Seonghoon ; Choi, Yoon La ; Kwon, Youngmi ; Song, Kyoung ; Gong, Gyungyub ; Shin, Young Kee. / Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. In: Frontiers in Oncology. 2019 ; Vol. 9.
@article{51bb1c3c01b54b3e87cea3a7e6b69611,
title = "Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer",
abstract = "Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared. Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4{\%}) patients were classified as low risk, and 244 (31.6{\%}) as high risk. Meanwhile, 134 (17.4{\%}), 516 (66.9{\%}), and 121 (15.7{\%}) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9{\%} when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer. Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.",
author = "Kwon, {Mi Jeong} and Lee, {Jeong Eon} and Joon Jeong and Woo, {Sang Uk} and Jinil Han and Kang, {Byeong Il} and Kim, {Jee Eun} and Youngho Moon and Lee, {Sae Byul} and Seonghoon Lee and Choi, {Yoon La} and Youngmi Kwon and Kyoung Song and Gyungyub Gong and Shin, {Young Kee}",
year = "2019",
month = "7",
day = "24",
doi = "10.3389/fonc.2019.00667",
language = "English",
volume = "9",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. / Kwon, Mi Jeong; Lee, Jeong Eon; Jeong, Joon; Woo, Sang Uk; Han, Jinil; Kang, Byeong Il; Kim, Jee Eun; Moon, Youngho; Lee, Sae Byul; Lee, Seonghoon; Choi, Yoon La; Kwon, Youngmi; Song, Kyoung; Gong, Gyungyub; Shin, Young Kee.

In: Frontiers in Oncology, Vol. 9, 667, 24.07.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

AU - Kwon, Mi Jeong

AU - Lee, Jeong Eon

AU - Jeong, Joon

AU - Woo, Sang Uk

AU - Han, Jinil

AU - Kang, Byeong Il

AU - Kim, Jee Eun

AU - Moon, Youngho

AU - Lee, Sae Byul

AU - Lee, Seonghoon

AU - Choi, Yoon La

AU - Kwon, Youngmi

AU - Song, Kyoung

AU - Gong, Gyungyub

AU - Shin, Young Kee

PY - 2019/7/24

Y1 - 2019/7/24

N2 - Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared. Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%) as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer. Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.

AB - Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asian patients with pN0-N1, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Methods: Formalin-fixed, paraffin-embedded breast cancer tissues previously analyzed using the Oncotype DX test were assessed using the GenesWell BCT test. The risk stratification by the two tests was then compared. Results: A total of 771 patients from five institutions in Korea were analyzed. According to the BCT score, 527 (68.4%) patients were classified as low risk, and 244 (31.6%) as high risk. Meanwhile, 134 (17.4%), 516 (66.9%), and 121 (15.7%) patients were categorized into the low-, intermediate-, and high-risk groups, respectively, according to the RS ranges used in the TAILORx. The BCT high-risk group was significantly associated with advanced lymph node status, whereas no association between RS risk groups and nodal status was observed. The concordance between the two risk stratification methods in the overall population was 71.9% when the RS low-risk, and intermediate-risk groups were combined into one group. However, poor concordance was observed in patients aged ≤50 years and in those with lymph node-positive breast cancer. Conclusions: The concordance between the BCT score and RS was low in women aged ≤50 years or with lymph node-positive breast cancer. Further studies are necessary to identify more accurate tests for predicting prognosis and chemotherapy benefit in this subpopulation.

UR - http://www.scopus.com/inward/record.url?scp=85072232643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072232643&partnerID=8YFLogxK

U2 - 10.3389/fonc.2019.00667

DO - 10.3389/fonc.2019.00667

M3 - Article

AN - SCOPUS:85072232643

VL - 9

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - 667

ER -